CAPRIN-1 Targeting Antibody for Selective Cancer Cell Destruction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using antibodies targeting cancer antigens often result in significant side effects due to the expression of these antigens in both cancer and normal cells, leading to damage of both cell types.
Innovation Solution
Development of an antibody specifically targeting CAPRIN-1, an intracellular protein that is specifically expressed on the surface of cancer cells, which is designed to have improved antitumor activity and minimized side effects by using a heavy chain variable region comprising amino acid sequences of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences of SEQ ID NOs: 9, 10, and 11, for use in treating and preventing various types of cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies targeting cancer antigens are administered, then antitumor activity is improved, but side effects worsen due to damage of normal cells expressing the same antigens
Solution Approach 1:
The patent applies local quality by targeting a specific intracellular protein (CAPRIN-1) that is locally expressed in cancer cells but not in normal cells. This selective targeting ensures that the antibody therapy acts only on the intended cancer cells while sparing normal cells, thereby improving the therapeutic index by resolving the contradiction between antitumor activity and side effects
Solution Approach 2:
The patent segments the target population by identifying a specific protein expression pattern unique to cancer cells (CAPRIN-1 intracellular protein). This segmentation allows the antibody to differentiate between cancer cells and normal cells, enabling selective destruction of cancer cells while preserving normal cells, thus resolving the technical contradiction
2Strength
If conventional antibody drugs targeting cancer antigens are used, then cancer cells are damaged, but normal cells are also damaged resulting in side effects
Solution Approach 1:
The invention employs local quality by targeting CAPRIN-1, an intracellular protein specifically expressed in cancer cells. This specific targeting ensures that the harmful effect (cell damage) is localized only to cancer cells expressing the target protein, while normal cells lacking this protein are spared, thereby resolving the contradiction between effective cancer cell damage and avoidance of normal cell damage
Data Source
AI summary
It is intended to identify a cancer antigenic protein specifically expressed on the surface of cancer cells and to provide an antibody targeting the antigenic protein and use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody comprising a heavy chain variable region comprising amino acid sequences of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences of SEQ ID NOs: 9, 10, and 11, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising this antibody or fragment as an active ingredient.